Thomas Jefferson University

Jefferson Digital Commons
Division of Internal Medicine Faculty Papers &
Presentations

Division of Internal Medicine

6-21-2022

Smartphone Apps for Diabetes Medication Adherence:
Systematic Review
Sheikh Mohammed Shariful Islam
Vinaytosh Mishra
Muhammad U Siddiqui
Jeban Chandir Moses
Sasan Adibi

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/internalfp
Part of the Internal Medicine Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Division of Internal Medicine Faculty Papers & Presentations by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Authors
Sheikh Mohammed Shariful Islam, Vinaytosh Mishra, Muhammad U Siddiqui, Jeban Chandir Moses,
Sasan Adibi, Lemai Nguyen, and Nilmini Wickramasinghe

JMIR DIABETES

Islam et al

Review

Smartphone Apps for Diabetes Medication Adherence: Systematic
Review
Sheikh Mohammed Shariful Islam1, MBBS, MPH, PhD; Vinaytosh Mishra2, PhD; Muhammad Umer Siddiqui3, MD,
MS; Jeban Chandir Moses4, MSc; Sasan Adibi4, PhD; Lemai Nguyen4, PhD; Nilmini Wickramasinghe5, PhD
1

Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Faculty of Health, Deakin University, Melbourne, Australia

2

College of Healthcare Management and Economics, Gulf Medical University, Ajman, United Arab Emirates

3

Department of Internal Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States

4

School of Information Technology, Deakin University, Burwood, Australia

5

Iverson Health Innovation Research Institute, Swinburne University of Technology, Melbourne, Australia

Corresponding Author:
Sheikh Mohammed Shariful Islam, MBBS, MPH, PhD
Institute for Physical Activity and Nutrition
School of Exercise and Nutrition Sciences, Faculty of Health
Deakin University
221 Burwood Highway
Burwood
Melbourne, 3125
Australia
Phone: 61 0392468393
Email: shariful@deakin.edu.au

Abstract
Background: Diabetes is one of the leading noncommunicable chronic diseases globally. In people with diabetes, blood glucose
levels need to be monitored regularly and managed adequately through healthy lifestyles and medications. However, various
factors contribute to poor medication adherence. Smartphone apps can improve medication adherence in people with diabetes,
but it is not clear which app features are most beneficial.
Objective: This study aims to systematically review and evaluate high-quality apps for diabetes medication adherence, which
are freely available to the public in Android and Apple app stores and present the technical features of the apps.
Methods: We systematically searched Apple App Store and Google Play for apps that assist in diabetes medication adherence,
using predefined selection criteria. We assessed apps using the Mobile App Rating Scale (MARS) and calculated the mean
app-specific score (MASS) by taking the average of app-specific scores on 6 dimensions, namely, awareness, knowledge, attitudes,
intention to change, help-seeking, and behavior change rated on a 5-point scale (1=strongly disagree and 5=strongly agree). We
used the mean of the app’s performance on these 6 dimensions to calculate the MASS. Apps that achieved a total MASS mean
quality score greater than 4 out of 5 were considered to be of high quality in our study. We formulated a task-technology fit matrix
to evaluate the apps for diabetes medication adherence.
Results: We identified 8 high-quality apps (MASS score≥4) and presented the findings under 3 main categories: characteristics
of the included apps, app features, and diabetes medication adherence. Our framework to evaluate smartphone apps in promoting
diabetes medication adherence considered physiological factors influencing diabetes and app features. On evaluation, we observed
that 25% of the apps promoted high adherence and another 25% of the apps promoted moderate adherence. Finally, we found
that 50% of the apps provided low adherence to diabetes medication.
Conclusions: Our findings show that almost half of the high-quality apps publicly available for free did not achieve high to
moderate medication adherence. Our framework could have positive implications for the future design and development of apps
for patients with diabetes. Additionally, apps need to be evaluated using a standardized framework, and only those promoting
higher medication adherence should be prescribed for better health outcomes.
(JMIR Diabetes 2022;7(2):e33264) doi: 10.2196/33264
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Introduction
Diabetes is one of the leading noncommunicable chronic
diseases globally and poses a significant challenge to
individuals’ physical and mental health and quality of life [1,2].
According to the International Diabetes Federation, in 2019,
approximately 463 million adults (9.3% of the global adult
population) aged 20-79 years lived with diabetes [3,4]. By 2045,
the number of people with diabetes is projected to surge to 700
million [3,4]. People with diabetes face long-term disease burden
and financial costs [5], and an estimated 79% of adults with
diabetes live in transitional countries [3]. In addition, more than
1.1 million children and adolescents are living with type 1
diabetes mellitus (T1DM) [3], involving autoimmune destruction
of pancreatic β-cells, resulting in insulin deficiency [6]. Aging,
urbanization, and lifestyle factors are causative factors of type
2 diabetes mellitus (T2DM) [4], which is a chronic metabolic
disorder characterized by insulin insensitivity as a result of
insulin resistance, declining insulin production, and eventual
pancreatic β-cell failure [7]. Further, deaths due to diabetes have
reached an alarming 4.2 million annually [3].
In patients with diabetes, blood glucose (BG) levels need to be
monitored regularly and managed adequately to maintain health
and well-being [8]. Nevertheless, almost half of the people with
diabetes remain nonadherent to their prescribed medications
[9-11], leading to uncontrolled diabetes, poor outcomes, and
lower quality of life [10,12-14]. Nonadherence to medical
therapy also results in increased absenteeism, hospitalization
risk, and need for health care, which have an enormous
economic impact on individuals and society [15,16]. Several
factors contribute to poor adherence to medication, including
complex dosing regimens, clinical inertia, safety concerns,
socioeconomic issues, costs of medication, ethnicity, patient
education and beliefs, social support, and polypharmacy
[13,17-19]. The Prospective Urban Rural Epidemiology (PURE)
study showed that 26.9% and 63.0% of households in
low-income countries could not afford metformin and insulin,
respectively [20]. High adherence to diabetes treatment has a
beneficial impact on BMI, lipid and glycemic control, and
emotional and physical performance [21]. Younger age, higher
numbers of medications, and higher hemoglobin A1c levels have
been associated with lower medication adherence among patients
with T2DM [22].
The widespread applications of information and communication
technologies (ICTs) in the health sector have resulted in
significant improvements in the health care delivery system,
such as promoting patient-centered health care, improving
quality of care, and educating health professionals and patients
[23]. ICTs, including web-based, mobile phone–based, and
digital technologies for electronic capture, storage, processing,
and information exchange, have been used to prevent and
manage chronic disease and improve medication adherence
[5,24-27]. Several studies have shown mobile health as an
effective and cost-effective approach for improving diabetes
https://diabetes.jmir.org/2022/2/e33264
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care [5,28-30]. The Global Observatory for eHealth, World
Health Organization, defines mobile health (mHealth) as
“medical and public health practice supported by mobile devices,
such as mobile phones, patient monitoring devices, personal
digital assistants, and other wireless devices.” mHealth
capitalizes on mobile phones’ core utility of voice and SMS as
well as more complex functionalities and applications, including
general packet radio service, mobile telecommunications, a
global positioning system, and Bluetooth technology [31].
Smartphone apps on diabetes management and self-management
are available for the public to download from major app stores,
including Google Play and Apple App Store [32,33]. Further,
several apps are available, which can collect health data,
providing clinical decision support systems and assisting with
medication adherence [34]. mHealth interventions are promising
for the treatment and management of diabetes [35]. Further,
there is strong evidence for the efficacy of apps for lifestyle
modification in patients with T2DM [36] and self-managed
tasks in improving health outcomes [37]. Apps have been
effective in increasing treatment adherence among patients with
various conditions, such as asthma, heart failure, hypertension,
and HIV [38]; medication adherence among patients with
depression, cardiovascular disease, Parkinson disease,
hypertension, and multimorbidity [39]; older adults with
coronary heart disease [40]; and essential hypertension [41].
Although a few recent reviews evaluated medication adherence
among individuals with diabetes [42-44], to our knowledge, no
systematic reviews have been undertaken to identify high-quality
apps and evaluate their features for diabetes medication
adherence. Hence, this study systematically reviews and
evaluates apps available for diabetes medication adherence and
presents the technical features of high-quality apps freely
available to the public in Google Play and Apple App Store.

Methods
Design
This study adopted the principles of a systematic review process
to identify and select apps, including using an app quality
assessment tool, a search strategy, predefined inclusion criteria
to screen apps, app rating and selection, and data extraction for
qualitative analysis.

App Selection and Assessment
Search Strategy
Globally, the dominating operating systems in the smartphone
market are Android and iOS [45]. Hence, we searched Google
Play (Android) and Apple App Store (iOS) in May 2020 for
apps used for diabetes medication adherence without
country-specific restrictions. The key search terms used
“Diabetes OR Diabetic OR Diabetics OR blood glucose OR
blood sugar” AND “medication OR medicine OR drugs OR
medication adherence OR medication support.” The search
produced a list of apps for screening. Figure 1 illustrates the
process of app selection from the respective app stores.
JMIR Diabetes 2022 | vol. 7 | iss. 2 | e33264 | p. 2
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Figure 1. App selection steps followed for Google Play and Apple App Store. MARS: Mobile App Rating Scale, T2DM: type 2 diabetes mellitus.

App Screening
Two researchers (VM and MS) screened the app titles and
descriptions from the app stores, using the inclusion and
exclusion criteria as shown in Textbox 1. In cases of
disagreement, the third reviewer (SMSI) intervened to evaluate
the situation and reach a consensus. We considered apps
available on both the Apple and Google platforms as single
apps. Further, we included apps with more than 100,000
downloads to identify the most common apps used in diabetes
medication adherence, following the approach of a similar study
to assess the quality of apps and perform a content analysis of
apps targeting medical adherence [46]. We evaluated
high-quality apps using the Mobile App Rating Scale (MARS)

[47]. Apps achieving a total mean quality score greater than 4
out of 5 in our study were considered to be of high quality [48].
MARS is a validated tool that measures app quality across 5
multidimensional layers to assess the quality of apps: (1)
engagement, (2) functionality, (3) aesthetics, (4) information,
and (5) app subjective quality [47]. The MARS scale gives equal
weightage to all 5 dimensions and uses a 5-point rating scale
from 1 to 5 with 1=inadequate and 5=excellent. The maximum
score for each dimension is 25 for engagement, 20 for
functionality, 15 for aesthetics, 35 for information, and 20 for
app subjective quality. We calculated the total mean score by
determining the mean of the average score for the 5 dimensions
[47].

Textbox 1. App selection criteria.
Inclusion criteria:
•

Apps for adults with type 2 diabetes

•

Apps with functionality supporting medication adherence or self-management features

•

Apps in the English language

•

Apps available for free and not requiring a paid subscription

•

Apps with >500 user ratings

Exclusion criteria:
•

Apps intended only for use by health care professionals and not general public

•

Apps not updated since January 1, 2018

•

Apps providing only diabetes education or suggestions for medication reminders

•

Apps with country restrictions

•

Apps that had any technical issues such as problems with downloading, logging in, and crashing

App Assessment
To determine which apps to include in this study, the apps
obtained after preliminary screening and application of the initial
inclusion criteria were downloaded and used by the two authors
(VM and MS) independently to test their functionality. After
discussion, the quality assessment was reported and in case of
https://diabetes.jmir.org/2022/2/e33264
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disagreements, input from the third author was sought. Further,
we calculated the mean app-specific score (MASS) by taking
the average of app-specific scores on 6 dimensions, namely,
awareness, knowledge, attitudes, intention to change,
help-seeking, and behavior change. These are also rated on a
5-point scale with 1=strongly disagree and 5=strongly agree.
We used the mean of the app’s performance on these 6
JMIR Diabetes 2022 | vol. 7 | iss. 2 | e33264 | p. 3
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dimensions to calculate the MASS [47]. We further assessed
the perceived impact of the app on the users’ knowledge,
attitudes, intentions to change, and the likelihood of actual
change on the target health behavior (diabetes medication
adherence in our case). Multimedia Appendix 1 presents an
app-specific evaluation and the MASS for the considered apps.

App Rating and Selection
We considered apps with a MASS greater than 4 to identify
high-quality apps for diabetes medication adherence.

Data Extraction
Two reviewers performed the data extraction. One reviewer
evaluated Apple App Store’s apps, and the other reviewer
evaluated Google Play apps. Before reviewing the apps, the
reviewers conferred and decided to include all the critical
features that the apps provide. We specifically focused on
medication reminders and the adherence features that the apps
offer. The reviewers extracted information on the app features
using a predetermined Excel (Microsoft Inc) sheet. The Excel
sheet was developed on the basis of a pilot app assessment
exercise with 5 apps with extensive features; the Excel sheet
was refined for this study. We excluded apps that could not be
assessed owing to country-specific or other restrictions. We

Islam et al
included additional features of free apps that were available
upon subscription only.

Data Analysis
We grouped the apps on the basis of the operating system (ie,
Android and iOS), presented the mean MARS rating, and
summarized the main features. We also presented the MASS
and app-specific rating for medication adherence based on
awareness, knowledge, attitude, intention to change,
help-seeking, and behavior change.

Results
Overview
We identified 249 apps in Google Play and 209 apps in the
Apple App Store. The initial inclusion criteria resulted in 63
and 39 Apps for Google Play and Apple App Store, respectively.
Finally, 8 apps with a MARS greater than 4 were included. The
mean MASS for the included apps was 4.2, and the average app
rating by users was 4.7. Figure 2 depicts the app selection
methodology followed for both Apple App Store and Google
Play for selecting the relevant apps that satisfy the selection
criteria.

Figure 2. Summary of app selection for review. MASS: mean app-specific score.

Characteristics of the Included Apps
All 8 apps were available in the Apple Store [49-56], 7 were
available in Google Play [49-55], and one app had the option
to be accessed through a web application and Amazon Alexa
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[56]. Given that all the apps were available in the Apple App
Store, we extracted information for the apps from the App Store.
Table 1 presents an overview of the apps. In contrast,
Multimedia Appendix 2 presents detailed information for each
app.
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Table 1. Overview of the apps.
Apps

Operating sys- Category
tem

Available languages, n

Data privacy
Identified

Deidentified

Seller

In-app purchases

Yes

Diabetes:M [49]

Android and
iOS

Medical

8

Yes

Yes

Chronic disease
software development company

mySugr - Diabetes
Tracker Log [52]

Android and
iOS

Medical

24

Yes

No

Digital health com- Yes
pany

Health2Sync [51]

Android and
iOS

Medical

4

Yes

No

Digital health com- Yes
pany

MyTherapy Pill Reminder [53]

Android and
iOS

Medical

30

No

Yes

Health, wellness,
and fitness

No

One Drop: Transform Android and
Your Life [54]
iOS

Health and fit- 11
ness

Yes

Yes

Software and
Technology services

Yes

Glucose Buddy Diabetes Tracker [50]

Android and
iOS

Medical

31

Yes

Yes

Individual

Yes

OneTouch Reveal
[55]

Android and
iOS

Medical

14

Yes

Yes

Diagnostic systems No
manufacturer

Sugarmate [56]

iOS

Medical

5

Required to pro- Required to provide with the next vide with the next
app update
app update

The Apple App Store apps were categorized as medical
[49-53,55,56] and health and fitness [54] apps. Including English
language, the apps were available in around 5 [51,56], 10
[49,54,55], 20 [52], and 30 languages [50,53]. Additionally, all
the apps had family sharing options (ie, the app could be shared
with and used by 6 family members) [49-56]. Apart from one
app [56], the apps defined their privacy policy explicitly,
defining the identified [49-52,54,55] and deidentified data
[49,50,53-55], although it differed between the apps. For
example, data such as health and fitness information, contact
information, identifiers, diagnostics, location, user content, and
usage data were considered “identified” data by one app [52].
In contrast, the same data were considered “deidentified” data
by another app [53]. Further, the apps were sold by software
companies [54,56], digital health companies [49,51,52,55],
health and fitness companies [53], and individuals [50]. Finally,
although all the apps were free [49-56], they had an in-app
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Software company No

purchase option [49-52,54]; that is, users had the option to pay
a prescribed amount to access additional features, such as
premium subscription features [49-52] and access to a coach
[54].
The compatible operating system (OS) version for the apps
varied drastically between the apps. For the apps to run
smoothly, 9.0 [49], 10.3 [56], 11.0 [51], 12.0 [50], 13.0 [53-55],
13.2 [52] or later versions of the OS were required.

App Features
Overview
In this section, we discuss the salient features of the apps
evaluated against standard parameters. However, we have
considered the free app features for this analysis (and we have
not considered the in-app features). Figure 3 illustrates the apps
and their corresponding features.
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Figure 3. Apps and their corresponding features. CGM: continuous glucose monitoring, DM: diabetes mellitus, T1DM: type 1 diabetes mellitus, T2DM:
type 2 diabetes mellitus.

Device Objective and Target Population
The primary objective of the apps was to manage diabetes
[49-52,55], manage diabetes and heart health [54], assist in
medication tracking [53], and function as a companion to a
continuous glucose monitoring (CGM) device [56]. Although
a few apps have been developed for the general population
irrespective of their medical condition [50,53,56], a few other
apps aimed to address the needs of patients with T2DM [51,54].
In contrast, other apps had functionalities to address the health
and well-being needs of patients with T1DM, T2DM, or
gestational diabetes mellitus [49,52,55]. The apps had age
ratings of 4+ [50-54,56] and 17+ [49,55].

BG Reading
The apps had different methodologies and used varying
technologies to capture the BG recordings. For example, some
apps could log in to the recordings manually [50,53]. In contrast,
a few other apps could capture CGM recordings from the
integrated BG monitoring (BGM) devices [55,56]. Nevertheless,
some other apps could manually log in the BG recordings and
CGM recordings from the integrated BGM devices
[49,51,52,54].

Health Data
In addition to recording BG readings, the apps had the option
to capture other health-related data, including food consumed
[49,50,52,54-56], blood pressure [50-54], weight [50-54], daily
activity and steps walked [52,54-56], and medication
[49,50,52,54]. Further, regarding food consumption, the apps
specifically considered the intake of carbohydrates
[49,50,52,55,56], protein [49], fats [49], and calories [49].
https://diabetes.jmir.org/2022/2/e33264
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Device Integration
There are various BGM or CGM devices available in the market,
and some apps could integrate and function with multiple
devices, such as Dexcom, OneTouch, and Accu-Chek
[49,51,54]. In contrast, other apps functioned exclusively with
a device, such as Accu-Chek [52] and Dexcom [49,50,54].
Moreover, an app developed by the seller of the OneTouch
device aimed to capture CGM recordings to perform analysis
tasks integrating other health parameters [55]. In contrast, a
seller not related to the Dexcom device developed an app to
capture the CGM readings in real time and perform other tasks
[56].

Reports
The apps had features to generate reports on BG levels, taking
into consideration other factors including food consumed
[49,50,52,54-56], physical activity [49,54,55], medication
[49,50,52,54], and other vital recordings [50,51,53,54,56]. From
the reports generated, the apps provided an overview of short
durations of captured data such as whenever the app is launched
[51]; hourly [50], daily [49,52,54,56], weekly [49,52,54], and
fortnightly [55]; and longer durations such as monthly [49,52,54]
and yearly [49]. Moreover, a few apps could alert individuals
when their BG levels dropped below or increased past threshold
values through notifications [49,55], SMS text messaging
[51,56], or phone calls [56].

Reminders
Forgetting to take medication is a significant cause of medication
nonadherence among patients [57]; hence, apps with reminders
could improve adherence. The apps had reminders to check
JMIR Diabetes 2022 | vol. 7 | iss. 2 | e33264 | p. 6
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glucose levels [49], take meals [49,54,55], medications [53,54],
exercise [53,54], and address other personalized medical needs
[51,55].

Adherence Motivation
To continuously support individuals in their journey of diabetes
medication adherence, apps have provided options to invite
clinicians, nutritionists, family, friends, and loved ones to view
their progress and accordingly assist them [51,53,54]; have
patient information for further support [49], providing
personalized tips [51,53,55]; and deliver an education plan
featuring 5-minute lessons [50]. In addition, a few apps had
gamification features (ie, elements of game-playing), such as
point-scoring, competition with others, and challenges to
encourage engagement [52,54-56].

Diabetes Medication Adherence
Among people with diabetes, optimum glycemic control is
essential, and good adherence is associated with a lower risk of
all-cause mortality and hospitalization [58]. Many models have
been studied to explore the acceptance and use of technologies.
One such model is task-technology fit (TTF). TTF states that a
technology should be effective in completing the assigned task,
which will lead to an increase in user performance and adoption
[59]. TTF rates the task characteristics and technology
characteristics of apps, which affects the effectiveness and
adoption of the apps by the user. Accordingly, in this section,
we used the TTF and quantified the effectiveness of apps in
diabetes adherence to evaluate whether the apps promote
adherence to diabetes medication [60,61]. A recent study used
TTF to evaluate the effectiveness of the mHealth app in
delivering health care services [62].

Primary prevention and mitigating the severity of diabetes
revolve around regular BG checks, food consumed, physical
activity, other vital readings, and adherence to medication [63].
Hence, they are the primary factors considered in this study.
Although apps have been found to improve awareness of
medication adherence and reduce self-reported barriers to
medication adherence among medication-nonadherent patients
with diabetes [64], a study observed that a large proportion of
diabetes self-management apps lacked features for enhancing
medication adherence and safety [65]. Consequently, among
the app features, we considered the overview (report generated
and graphically presented for a period), reminders (customized
alerts to perform tasks), notifications (alerts when BG shoots
up or drops below the threshold), assistance (additional support
provided by various stakeholders), and motivation (assistance
from loved ones and challenges through gamification) as the
imperative app features needed to support an individual in
diabetes medication adherence.
Table 2 presents a TTF matrix for diabetes medication adherence
to evaluate the apps against the defined primary factors and app
features. In the matrix, we have marked “yes” when factors and
features are available. We then totaled the score for primary
factors and app features separately. We defined a score of 5 in
both primary factors and app features as apps assisting in very
high adherence, 4 and above in either primary factors or app
features as apps assisting in high adherence, and a score of 3
and above in either primary factors or app features as apps
assisting in moderate adherence. We further defined a low
adherence app as apps scoring 2 and above in either primary
factors or app features and any score below 2 for primary factors
or app features as apps resulting in poor adherence.

Table 2. The task-technology fit matrix for diabetes medication adherence.
App

Primary factors

App features

Blood
glucose

Food Physical
Activity

Medication Vital Score Overview Reminder
signs

Notification

Assistance

Motivation

Score

Diabetes:M
[49]

Yes

Yes

Yes

Yes

No

4

Yes

Yes

Yes

Yes

No

4

mySugr - Diabetes Tracker
Log [52]

Yes

Yes

No

Yes

No

3

Yes

No

No

No

Yes

2

Health2Sync
[51]

Yes

No

No

No

Yes

2

Yes

Yes

Yes

Yes

Yes

5

MyTherapy Pill Yes
Reminder [53]

No

No

No

Yes

2

Yes

No

Yes

Yes

3

One Drop:
Yes
Transform Your
Life [54]

Yes

Yes

Yes

Yes

5

Yes

Yes

No

No

Yes

3

Glucose Buddy Yes
Diabetes Tracker [50]

No

No

Yes

Yes

3

Yes

No

No

Yes

No

2

OneTouch Reveal [55]

Yes

Yes

Yes

Yes

No

4

Yes

Yes

Yes

Yes

Yes

5

Sugarmate [56]

Yes

Yes

No

Yes

Yes

4

Yes

No

Yes

No

Yes

3
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According to our evaluation, none of the apps assists in very
high adherence, and there are no poor-adherence apps. In
addition, we found that 3 apps each assisted in high adherence
(25%) [49,55] and moderate adherence to diabetes medication
(25%) [54,56]. In contrast, 4 other apps were in the low
adherence category in assisting with diabetes medication
adherence (50%) [50-53].

Discussion
Principal Findings
In this systematic review, we identified 8 high-quality apps
publicly available in the Apple App Store and Google Play free
of charge. The mean MASS of the apps was 4.2, while the
average user ratings was 4.7. Only 2 apps showed high
adherence and 2 apps showed moderate adherence, while half
of the apps showed low adherence. However, since the global
market is poised for rapid growth and could have widespread
implications in delivering personalized health care [66],
interoperable mHealth solutions available in the Apple App
Store and Google Play are generally designed and developed
for widespread adaptability. Our systematic review suggests
evaluating apps using a standardized framework before
prescribing them to patients with diabetes, and using behavioral
theories for improving medication adherence.
All the apps were available in English and more than 5 other
languages [49-56]. Moreover, bilingual English-speaking
patients expressed the need for language translation to
understand and communicate using the apps [67], and the
selected apps could address this concern through the
multilanguage option provided. However, globally, 79% of
adults with diabetes live in transitional countries [3]. An increase
in mobile phone subscriptions over the years, including in
transitional countries [68], and the constant technological
advancements in mobile phones [69] promote mHealth as
effective for use in transitional countries having barriers, such
as lack of infrastructure and equipment and technology gaps
[70]. Hence, if the selected apps have languages that
predominate in transitional countries with a higher prevalence
of diabetes, they might assist in diabetes management, reducing
the burden on the health care system and curbing mortality rates.
Deidentification is essential for protecting patient privacy and
removing identifiers that directly or indirectly point to a person
[71]. However, there is variability in the definition of
deidentification [72]. For instance, among the considered apps,
health and fitness, contact information, identifiers, diagnostics,
location, user content, and usage data were considered identified
data by one app [52]. In contrast, the same data were deemed
deidentified data by another app [53]. This discrepancy could
be due to differences in definitions and legal practice followed
in countries where the apps have been developed [72]. Hence,
health care apps developed in accordance with the guidelines
of legislation, such as the US Health Insurance Portability and
Accountability Act and the European General Data Protection
Regulation, could have uniformity in defining identified and
deidentified data [72]. Accordingly, following global regulatory
guidelines could bring uniformity in the use of identified and
deidentified data.
https://diabetes.jmir.org/2022/2/e33264

XSL• FO
RenderX

Islam et al
In-app purchases permit the user to purchase added services
from within an app, and 5 apps considered in this study had this
feature [49-52,54]. Remarkably, in-app purchase options work
well in promoting health apps wherein the essential functions
are offered freely [73]. However, the intention to upgrade to a
paid subscription is driven by the subscription features, benefits,
and price value [74]. Hence, developing free health apps with
in-app purchase options will be necessary to promote the app;
however, the content should provide sufficient value to retain
subscriptions [74].
A few apps described in this study could be used by all patients
with diabetes [50,53,56]. In contrast, other apps were
specifically targeted to patients with T2DM [51,54] or to those
with T1DM, T2DM, or gestational DM [49,52,55]. Nevertheless,
apps with specific descriptions were sought more by users
compared to those with general descriptions [75]. Some apps
had an age rating of ≥4 [50-54,56] and ≥17 [49,55]. T1DM
affects children [3], and although some apps were indicated as
suitable for patients with T1DM, the age rating was ≥17 [49,55].
Another app had an age rating of ≥4 and could be used by
patients with T1DM [52]. Hence, developing apps with specific
descriptions and appropriate age ratings could assist the
appropriate target population.
We have considered physiological factors influencing diabetes
and app features to develop and assess apps using the TTF
matrix.

Limitations of the Research
This review had certain limitations. First, in this study, we
included apps that had greater than 500 ratings. Therefore, we
could have eliminated several new apps with fewer than 500
reviews, but that might have had a higher MASS. Second, we
included only apps in the English language, possibly missing
effective apps in languages other than English. Third, our search
date was limited to May 2020. However, the constraints
associated with the severity of the COVID-19 pandemic could
have enabled the development and usage of apps that satisfied
our selection criteria. Finally, we limited our search to the apps
available in the major app stores: Apple App Store and Google
Play. However, these stores account for 80% (4.41 million) of
the global apps as of May 2020 [76].

Implications and Future Research
Our findings provide guidelines for app developers to develop
an app that assists in diabetes medication adherence. Further,
several apps are very likely to be developed and prescribed
during the pandemic period [77,78]. Therefore, evaluating the
apps using our framework could help the apps to provide high
medication adherence for better health and well-being of patients
with diabetes. With the advancement in smartphone technology,
various health vitals could be captured and transferred in real
time for analysis [79-81]. The application of machine learning
and big data could provide a wealth of predictive information
to the patient and to health care professionals [82-87].
Furthermore, high-quality apps coupled with evidence-based
ICT programs using user-centric designs, wearable device, and
machine learning approaches could be used to provide
personalized interventions for people with diabetes [84,87-93].
JMIR Diabetes 2022 | vol. 7 | iss. 2 | e33264 | p. 8
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Hence, our findings could have practical and research
implications for diabetes medication adherence.

Conclusions
Our framework to evaluate smartphone apps in promoting
diabetes medication adherence has considered physiological

Islam et al
factors influencing diabetes and app features. Therefore, our
findings could have positive implications for the design and
development of apps for patients with diabetes. Additionally,
the available apps could be evaluated in accordance with our
framework, and those apps promoting higher medication
adherence could be prescribed for better health outcomes.
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